Gsa Capital Partners LLP Novavax Inc Transaction History

Gsa Capital Partners LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$3.89 - $20.97 $77,978 - $420,364	20,046 New	20,046 $254,000
Q3 2023 Nov 15, 2023	BUY	$6.81 - $9.74 $81,883 - $117,113	12,024 New	12,024 $87,000
Q1 2023 May 12, 2023	SELL	$5.76 - $12.48 $73,486 - $159,219	-12,758 Reduced 52.46%	11,561 $80,000
Q4 2022 Feb 13, 2023	BUY	$8.86 - $25.04 $7,548 - $21,334	852 Added 3.63%	24,319 $250,000
Q3 2022 Nov 14, 2022	BUY	$18.2 - $76.12 $427,099 - $1.79 Million	23,467 New	23,467 $427,000
Q2 2022 Aug 09, 2022	SELL	$36.28 - $75.29 $196,057 - $406,867	-5,404 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$69.73 - $142.9 $221,741 - $454,422	3,180 Added 142.99%	5,404 $398,000
Q4 2021 Feb 14, 2022	BUY	$134.56 - $217.97 $299,261 - $484,765	2,224 New	2,224 $318,000
Q3 2019 Nov 12, 2019	SELL	$4.02 - $7.84 $134,879 - $263,047	-33,552 Closed	0 $0
Q2 2019 Aug 06, 2019	BUY	$4.93 - $12.2 $165,411 - $409,334	33,552 New	33,552 $197,000

290

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $666M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.